Inhibitor pretreatment | CCL cell viability (n = 8) | CaCL cell viability (n = 8) | |||
---|---|---|---|---|---|
 |  | SNP treatment | SNP treatment | ||
 |  | - | + | - | + |
zVAD.fmk | 0 | 100 ± 6.0 | 75.5 ± 3.1 | 100 ± 5.9 | 73.6 ± 2.4 |
 | 100 μM | 92.5 ± 5.3 | 84.5 ± 4.3 | 92.2 ± 6.3 | 88.2 ± 3.6* |
CalC | 0 | 100 ± 11.3 | 79.9 ± 5.3 | 100 ± 5.9 | 78.2 ± 7.2 |
 | 25 nM | 93.5 ± 6.9 | 73.4 ± 3.3 | 100 ± 6.0 | 68.7 ± 7.0 |
PD98059 | 0 | 100 ± 5.6 | 75.8 ±6.4 | 100 ± 4.1 | 74.7 ± 9. 3 |
 | 10 μM | 81.2 ± 7.2* | 61.8 ± 3.1* | 78.3 ± 7.2* | 52.2 ± 9.2* |
SB202190 | 0 | 100 ±11.3 | 73.4 ± 5.4 | 100 ± 6.0 | 74.2 ± 7.7 |
 | 10 μM | 74.2 ±2.1* | 65.9 ± 4.5 | 75.2 ± 5.8* | 79.8 ± 2.4 |
Genistein | 0 | 100 ± 6.0 | 69.6 ± 6.1 | 100 ± 5.8 | 72.3 ± 5.7 |
 | 50 μM | 101 ± 6.4 | 97.4 ±9.3** | 106.1 ±6.3 | 101.9 ± 2.5** |
NS-398 | 0 | 100 ± 5.4 | 64.9 ± 3.6 | 100 ± 5.4 | 63.2 ± 4.1 |
 | 50 μM | 89.5 ± 17.7 | 78.1 ± 3.9* | 88.5 ± 4.7* | 88.8 ± 2.5** |
 | 100 μM | 74.7 ± 14.4 | 75.3 ± 4.2* | 81.8 ± 12.1 | 92.4 ± 2.7** |
SN-50 | 0 | 100 ± 8.3 | 74.6 ± 3.8 | 100 ± 8.4 | 81.2 ± 2.4 |
 | 50 μM | 97.3 ± 8.6 | 64.4 ± 12.6 | 101.4 ± 4.5 | 67.3 ± 2.7* |
PDTC | 0 | 100 ± 8.3 | 74.6 ± 3.8 | 100 ± 8.4 | 81.2 ± 2.4 |
 | 10 μM | 42.7 ± 7.7** | 5.5 ± 1.9** | 43.8 ± 2.3** | 2.1 ± 1.7** |
Uric acid | 0 | 100 ± 9.2 | 73.5 ± 5.4 | 100 ± 5.6 | 78.2 ± 2.4 |
 | 0.5 mM | 103.6 ± 9.5 | 102.7 ± 12.1* | 101.9 ± 6.2 | 94.6 ± 5.9* |
PTIO | 0 | 100 ± 6.2 | 64.9 ± 2.6 | 100 ± 9.3 | 61.2 ± 4.6 |
 | 5 μM | 87.9 ± 7.3 | 80.9 ± 1.5* | 96.2 ± 9.6 | 73.8 ± 3.2* |
Taxifolin | 0 | 100 ± 3.7 | 76.2 ± 4.2 | 100 ± 5.6 | 74.3 ± 7.7 |
 | 100 μM | 91.6 ± 11.5 | 84.8 ± 10.6 | 101.3 ± 4.1 | 97.3 ± 6.8* |